Nouscom AG: Poster on initial results from Phase 1 trial for NOUS-209, an “off-the-shelf” neoantigen cancer vaccine, in MSI-H solid tumors will be presented at ESMO

Our abstract “Initial Results from a Phase I Study of NOUS-209, an Off-the-Shelf Viral Vectored Immunotherapy Encoding 209 Shared Frame Shift Peptide Neoantigens, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite Instability.” was accepted to be presented as an e-poster at the European Society for Medical Oncology (ESMO) congress.

E-poster number: 1004P
Primary author: Dr. Michael J. Overman, MD Anderson Cancer Center

The poster will be released on the ESMO website on 16 September at 10:30 CEST (https://www.esmo.org/meetings/esmo-congress-2021).